Advertisement
A re-broadcast of the conference call will be available at www.vasogen.comand may also be accessed by:
Vasogen is a biotechnology company engaged in the research and commercialdevelopment of therapies designed to target the destructive inflammatoryprocess associated with the development and progression of cardiovascular andneurodegenerative disorders. The Company's lead product, the Celacade(TM)System, is designed to activate the immune response to apoptosis - animportant physiological process that regulates inflammation. Celacade hasreceived European regulatory approval under the CE Mark for chronic heartfailure and is being marketed in the EU by Grupo Ferrer Internacional, S.A.Celacade is also in late-stage clinical development for the treatment ofchronic heart failure in the United States. Vasogen is also developing a newclass of drugs for the treatment of certain neuro-inflammatory disorders.VP025 is the lead drug candidate from this new class.
Advertisement
Certain statements contained in this press release, the upcomingconference call and webcast, or elsewhere in our public documents constitute"forward-looking statements" within the meaning of the United States PrivateSecurities Litigation Reform Act of 1995 and/or "forward-looking information"under the Securities Act (Ontario). These statements may include, withoutlimitation, plans to advance the development of Celacade(TM) or VP025, plansto fund our current activities, statements concerning our partneringactivities, health regulatory submissions, strategy, future operations, futurefinancial position, future revenues and projected costs. In some cases, youcan identify forward-looking statements by terminology such as "may", "will","should", "expects", "plans", "anticipates", "believes", "estimated","predicts", "potential", "continue", "intends", "could", or the negative ofsuch terms or other comparable terminology. We made a number of assumptions inthe preparation of these forward-looking statements, including assumptionsabout the nature, size, and accessibility of the market for Celacade in thetreatment of chronic heart failure, particularly in Europe, the regulatoryapproval process leading to commercialization and the availability of capitalon acceptable terms to pursue the development of Celacade, and the feasibilityof additional trials. You should not place undue reliance on ourforward-looking statements which are subject to a multitude of risks anduncertainties that could cause actual results, future circumstances or eventsto differ materially from those projected. These risks include, but are notlimited to, the outcome of further ongoing analysis of the ACCLAIM trialresults, the requirement or election to conduct additional clinical trials andthe size and design of any such trials, delays or setbacks in the regulatoryapproval process, difficulties in the maintenance of existing regulatoryapprovals, securing and maintaining corporate alliances, the need foradditional capital and the effect of capital market conditions and otherfactors on capital availability, the potential dilutive effects of anyfinancing, risks associated with the outcomes of our preclinical and clinicalresearch and development programs, the adequacy, timing, and results of ourclinical trials, competition, market acceptance of our products, theavailability of government and insurance reimbursements for our products, thestrength of intellectual property, reliance
